Procognia showcases the first human kinase protein array for drug screening at SBS, Geneva

Geneva, CH: September 12, 2005, Procognia, a leader in cutting edge proteomic technologies, announces the introduction of the first human kinase protein function array for use in compound profiling and other drug screening applications. Rachel Fallon, VP Research & Development and Operations, will present the novel array technology during a tutorial session as part of the SBS (Society of Biomolecular Screening) conference programme.

Procognia will present a competition assay in which potential small molecule inhibitors are tested for binding to kinases in the presence of fluorescently labelled universal binder. The tutorial will demonstrate selectivity data and IC50 values obtained against an array of human kinases. It will also show that this assay format can be applied to compound profiling against hundreds of kinases with same-day results.
The new human kinase array is the latest addition to Procognia's expanding portfolio of functional protein arrays. These arrays and assays are developed on a custom design basis directly with Procognia. Life science catalogue products for themed arrays of proteins of interest will also be available via an exclusive marketing agreement with Sigma-Aldrich. Whatever the customer requirement, Procognia's protein function arrays can increase the productivity of researchers' drug discovery and development programmes by delivering fast and reproducible results. Using proprietary tagging technology which ensures arrayed proteins are folded and therefore functional, hundreds of proteins can be assayed in hours. As well as applying the array technology for protein:small molecule interaction, Procognia's functional protein arrays are also used for other applications such as protein:protein interactions and kinase substrate identification.
Ron Long, CEO and Chairman of Procognia, said, "We are developing platforms at Procognia designed to improve productivity in drug discovery, development and manufacture. Our aim is to help develop a more comprehensive understanding of proteins as targets and as therapeutics and today we are working on a programme to array the proteome in druggable classes."

About BroadLight, Inc.
Procognia Ltd, a 2004 World Economic Forum Technology Pioneer award winner, is focused on developing and commercializing its cutting edge proprietary technologies to enable the unravelling of disease mechanisms and the discovery and development of drugs to treat those diseases. In addition to developing its glycoanalysis technology, Procognia has developed arrays of biologically related proteins that retain their physiological function in the array format. Procognia was formed in April 2002 with a corporate headquarters and manufacturing in Maidenhead, United Kingdom. Commercial operations are run from the United Kingdom and Exton, PA, United States, and supported by R&D facilities in Maidenhead, United Kingdom and Ashdod, Israel. Further information available at www.procognia.com.

Contacts:
Sue Cotrel
VP Marketing, PROCOGNIA Ltd, +44 1628 513503, e-mail: sue.cotrel@procognia.com